Using a more basic chemical design, molecular glues could use the cell’s natural breakdown mechanisms to solve some PROTAC constraints 9. Apart from small molecules, non-small molecule strategies such ...

Roche (RHHBY Quick Quote RHHBY - Free Report) announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics. Per the agreement, Roche’s Genentech will acquire ...

Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and ...

Dr Fatima Cardoso, director of the Breast Cancer Unit at Champalimaud Cancer Centre in Lisbon, Portugal, is a leader in a global initiative [2] to improve the care and treatment of persons with ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

SAN ANTONIO — Adding the CDK 4/6 blocker palbociclib to standard endocrine and antihuman epidermal growth factor receptor 2 (HER2) therapies in metastatic hormone receptor (HR)–positive, HER2-positive ...

BUFFALO, N.Y. — Worldwide, more than a million breast cancer patients have been treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which slow or stop the uncontrolled multiplication of ...

Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become ...

US FDA extends PDUFA date and seeks additional data from AstraZeneca’s NDA for camizestrant in combo with a CDK 4/6 inhibitor to treat HR-positive, HER2-negative advanced breast ...

UPPSALA, SE / ACCESS Newswire / May 26, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, today announced an expansion of an ...